Enlivex Therapeutics Ltd. closed a $21 million convertible debt financing with The Lind Partners on March 23, 2026, generating net proceeds of approximately $18.7 million before fees. The transaction was announced on March 24, 2026 and will be recorded as a convertible note with a fixed conversion price of $2.69175 per share, a 264 % premium to the Nasdaq closing price of $1.03 on March 20, 2026.
The financing is part of Enlivex’s dual‑engine strategy, which couples the development of its longevity therapeutic, Allocetra™, with a prediction‑markets treasury approach centered on the RAIN token. Enlivex exercised an option to acquire 3,030,303,030 RAIN tokens at $0.0033 per token for $10 million, a 62 % discount to the March 22 closing price. The company’s board also approved a share‑repurchase program of up to $20 million, signaling a willingness to return capital while maintaining a robust balance sheet.
Enlivex’s FDA clearance of its Allocetra™ Phase 2b trial for knee osteoarthritis marks a significant milestone for the company’s core biopharmaceutical pipeline. CEO Oren Hershkovitz said, "This milestone represents an important step toward our mission of improving the quality of life of an aging population that is suffering from this debilitating disease with poor availability of treatment options." The dual‑engine approach is intended to diversify revenue streams and leverage the growing prediction‑markets ecosystem.
The company remains unprofitable, reporting a loss of $0.54 per share over the last twelve months, and its debt‑to‑equity ratio stood at 4.01 % as of Q2 2025. The convertible note’s high conversion premium reflects management’s confidence in future share price appreciation, while the RAIN token purchase underscores a strategic bet on the emerging prediction‑markets space. The share‑repurchase program, subject to regulatory approval, provides a potential upside for shareholders if the company’s valuation improves.
Enlivex also announced its voluntary delisting from the Tel Aviv Stock Exchange, with the last trading day scheduled for April 23, 2026. Shares will continue to trade on Nasdaq, consolidating the company’s listing strategy and simplifying regulatory compliance.
The financing, token acquisition, and share‑repurchase program together illustrate Enlivex’s effort to balance capital allocation between its clinical pipeline and a high‑risk, high‑potential digital‑asset strategy, while maintaining liquidity for future growth initiatives.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.